Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.
复制标题

在营养不良的MDX小鼠中PIP-PMO治疗后,预防运动诱导的心肌病。

DOI:
10.1038/srep08986
复制
发表时间:
2015-03-11
期刊:
影响因子:
4.6
通讯作者:
Wood MJ
Wood MJ
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Betts CA;Saleh AF;Carr CA;Hammond SM;Coenen-Stass AM;Godfrey C;McClorey G;Varela MA;Roberts TC;Clarke K;Gait MJ;Wood MJ

文献摘要

参考文献

被引文献

相似文献

Duchenne肌营养不良症(DMD)是一种由DMD基因突变引起的致命性神经肌肉疾病。除了骨骼肌萎缩外,DMD患者还会发展成心肌病,这对死亡率有很大的影响。反义寡核苷酸(AOS)是一种很有前景的DMD治疗方法,通过跳过外显子来恢复Dystrophin蛋白的功能。然而,目前AOS的一个主要限制是心脏中缺乏dystrophin校正。PIP多肽-Aos在心肌中具有很高的活性。为了确定它们的治疗价值,对营养不良的MDX小鼠进行强迫运动,以建立DMD心脏表型模型。重复多肽-AO治疗可导致高水平的心肌肌营养不良蛋白,从而防止运动诱导的心肌病进展,使心脏大小正常化,并稳定其他心脏参数。经治疗的小鼠也表现出显著的减少心肌纤维化和改善肌膜完整性。这项工作表明,在营养不良的DMD小鼠中,由Pip多肽-AOS恢复的高水平的心脏肌营养不良蛋白可以防止运动后心肌病和病理的进一步恶化。
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder caused by mutations in the Dmd gene. In addition to skeletal muscle wasting, DMD patients develop cardiomyopathy, which significantly contributes to mortality. Antisense oligonucleotides (AOs) are a promising DMD therapy, restoring functional dystrophin protein by exon skipping. However, a major limitation with current AOs is the absence of dystrophin correction in heart. Pip peptide-AOs demonstrate high activity in cardiac muscle. To determine their therapeutic value, dystrophic mdx mice were subject to forced exercise to model the DMD cardiac phenotype. Repeated peptide-AO treatments resulted in high levels of cardiac dystrophin protein, which prevented the exercised induced progression of cardiomyopathy, normalising heart size as well as stabilising other cardiac parameters. Treated mice also exhibited significantly reduced cardiac fibrosis and improved sarcolemmal integrity. This work demonstrates that high levels of cardiac dystrophin restored by Pip peptide-AOs prevents further deterioration of cardiomyopathy and pathology following exercise in dystrophic DMD mice.
DOI: 10.1007/s00246-004-0689-2
发表时间: 2005-01-01
影响因子: 1.6
作者:
Kirchmann, C;Kececioglu, D;Dittrich, S
通讯作者: Dittrich, S
DOI: 10.1038/mtna.2012.30
发表时间: 2012-08-14
期刊: Molecular therapy. Nucleic acids
影响因子: --
作者:
通讯作者: --
DOI: 10.1002/mus.21783
发表时间: 2010-12-01
期刊: MUSCLE & NERVE
影响因子: 3.4
作者:
Costas, Jeffrey M.;Nye, David J.;Plochocki, Jeffrey H.
通讯作者: Plochocki, Jeffrey H.
DOI: 10.1056/nejmoa1011367
发表时间: 2011-04-21
影响因子: 158.5
作者:
Goemans, Nathalie M.;Tulinius, Mar;van Deutekom, Judith C.
通讯作者: van Deutekom, Judith C.
DOI: 10.1002/jgm.1288
发表时间: 2009-03-01
影响因子: 3.5
作者:
Heemskerk, Hans A.;de Winter, Christa L.;Aartsma-Rus, Annemieke
通讯作者: Aartsma-Rus, Annemieke